|Bid||0.8576 x 800|
|Ask||0.8803 x 900|
|Day's Range||0.8400 - 0.8946|
|52 Week Range||0.3100 - 1.3900|
|Beta (5Y Monthly)||1.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 18, 2021 - Feb 22, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced today the following updates:
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the third group in the Phase I inhaled Ampion™ clinical study is being treated following clearance by the Safety Monitoring Committee (SMC) who found Ampion to be safe and well-tolerated after reviewing the results from the first and second treatment groups.
We can readily understand why investors are attracted to unprofitable companies. Indeed, Ampio Pharmaceuticals...